KRAS G12D Inhibitor's $2.13B Deal Tests Cross-Border Tech Transfer

Merck has secured exclusive global rights to SPR2015, an investigational preclinical oral inhibitor targeting the active form of KRAS G12D, from Shanghai-based SciBrunch Therapeutics.1 In exchange for Merck now holding worldwide rights to develop, manufacture, and commercialize the compound, SciBrunch receives a $400 million upfront payment and is eligible for milestone payments tied to development, commercialization, and other activities across multiple indications. The total potential value is $2.13 billion.

"Evidence continues to accumulate for the therapeutic potential of targeting the KRAS pathway, a well-characterized factor in tumor cell growth," said George Addona, senior vice president, discovery, preclinical development and translational medicine, Merck Research Laboratories, in a press release.1 "This agreement complements and diversifies our expanding pipeline of precision targeted candidates with SPR2015, a potent engineered inhibitor for one of the most prevalent mutant forms of KRAS found in human cancers."

What Makes KRAS G12D a Sought-After Target?

KRAS G12D is the most common oncogenic RAS mutation in human tumors.1 Substitution of aspartate for glycine at position 12 leaves KRAS in an active state, continuously signaling for cell proliferation and survival.

SPR2015 is described as a molecular glue inhibitor that engages the ON form of the mutant protein.1 It showed nanomolar antiproliferative activity across multiple KRAS G12D-mutant cell lines while maintaining selectivity over wild-type cells, and it demonstrated monotherapy antitumor efficacy in cell-derived and patient-derived xenograft models. The RAS field has advanced quickly in 2026. Molecular glues, meanwhile, remain an emerging modality; developers are still working to overcome the off-target effects of first-generation therapies.

"Since our founding, SciBrunch has remained focused on advancing innovative therapies targeting the RAS pathway and is committed to delivering transformative treatment options for patients with pancreatic, colorectal, lung, and other major malignant tumors," said Tao Hu, founder, chairman and CEO, SciBrunch.1 "This agreement with Merck not only validates the R&D strength of our platform but also underscores the potential of SPR2015 in addressing longstanding unmet medical needs in oncology. We are excited that Merck, a global leader in oncology, will take SPR2015 forward."

What Is SPR2015's Path to the Clinic?

With SPR2015 originating in Shanghai and not yet in human testing, where Merck conducts its early studies may carry regulatory weight.2 In a recent FDA Voices post, the leaders of four FDA centers said FDA is adding resources for foreign inspections, including more phase I and early-stage trials, and will apply heightened scrutiny to foreign studies not conducted under an investigational new drug application. The agency also warned that sites denying or conditioning inspection access can jeopardize data acceptance, urging sponsors to treat inspectability as a material factor in regulatory strategy and to discuss data provenance at early pre-submission meetings.

Why Does This Deal Matter?

The agreement reflects a sourcing pattern that increasingly shapes R&D pipelines at large pharmaceutical companies: licensing early assets from China-based developers.1 Because Merck acquired manufacturing rights at the preclinical stage, synthetic routes, analytical methods, and specifications developed by SciBrunch will likely need to be transferred to Merck's internal network or contract manufacturing partners ahead of first-in-human studies. For compounds that rely on precise three-dimensional interactions to stabilize protein complexes, control of stereochemistry, impurity profiles, and solid form can be central to demonstrating consistent performance across sites and scales.

The oral small-molecule format is notable as unlike antibody-drug conjugates or cell therapies, SPR2015 can draw on established drug substance and oral solid dose infrastructure, which may simplify scale-up if the program advances.1 Still, a $400 million upfront commitment for a preclinical asset signals how aggressively large companies are competing for differentiated RAS-directed candidates, and how early development and manufacturing planning may need to begin.

References

1. Merck & Co., Inc. Merck enters into exclusive global license agreement with SciBrunch Therapeutics for SPR2015, an investigational oral KRAS G12D (ON) inhibitor. Published September 28, 2026. Accessed September 28, 2026. https://www.merck.com/news/merck-enters-into-exclusive-global-license-agreement-with-scibrunch-therapeutics-for-spr2015-an-investigational-oral-kras-g12d-on-inhibitor/
2. Davis M, Mikhail K, Tarver M, de Claro RA. Good clinical practices are not optional: the FDA’s commitment to human subject protections and gold standard science in an era of global clinical research. FDA Voices. Published September 2, 2026. Accessed September 28, 2026. https://www.fda.gov/news-events/fda-voices/good-clinical-practices-are-not-optional-fdas-commitment-human-subject-protections-and-gold-standard